Improving rate of decline of FEV1 in young adults with cystic fibrosis.
about
Exacerbations in cystic fibrosis: 2 . prevention.A new scoring system in Cystic Fibrosis: statistical tools for database analysis - a preliminary report.Lessons learned from a randomized trial of airway secretion clearance techniques in cystic fibrosisClinical significance of microbial infection and adaptation in cystic fibrosis.A cross-sectional study of growth, nutritional status and body proportions in children and adolescents at a medical center specializing in the treatment of cystic fibrosis in Poland.Factors related to changes in the quality of life among Polish adolescents and adults with cystic fibrosis over a 1-year period.Serum Iron Level Is Associated with Time to Antibiotics in Cystic FibrosisVariation in lung function is associated with worse clinical outcomes in cystic fibrosisTelemonitoring in Cystic Fibrosis: A 4-year Assessment and Simulation for the Next 6 YearsPregnancy outcomes in cystic fibrosis: a 10-year experience from a UK centreDevelopment, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis.Vitamin D deficiency is associated with pulmonary exacerbations in children with cystic fibrosis.Current status and future directions of gene and cell therapy for cystic fibrosis.Putting lung function and physiology into perspective: cystic fibrosis in adults.New and Emerging Treatments for Cystic Fibrosis.Effects of Autogenic Drainage on Sputum Recovery and Pulmonary Function in People with Cystic Fibrosis: A Systematic Review.Effect of residential proximity to major roadways on cystic fibrosis exacerbations.Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.Lung function comparison between two decades in cystic fibrosis children: A single centre study.Pulmonary exacerbations in cystic fibrosis and bronchiectasisAntimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.Differences in hyperpolarized (3) He ventilation imaging after 4 years in adults with cystic fibrosis.Cystic fibrosis liver disease: to transplant or not to transplant?Clinical, nutritional and spirometric evaluation of patients with cystic fibrosis after the implementation of multidisciplinary treatment.The emergence of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis patients on inhaled antibiotics.Feasibility and variability of measuring the Lung Clearance Index in a multi-center setting.Effect of oral glycine on the clinical, spirometric and inflammatory status in subjects with cystic fibrosis: a pilot randomized trial.Physiological markers of exercise capacity and lung disease severity in cystic fibrosis.Comparative Effectiveness Research in Pediatric Respiratory Disease: Promise and Pitfalls.A semiquantitative MRI-Score can predict loss of lung function in patients with cystic fibrosis: Preliminary results.Longitudinal Assessment of Children with Mild Cystic Fibrosis Using Hyperpolarized Gas Lung Magnetic Resonance Imaging and Lung Clearance Index.Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis.Long-term impact of liver transplantation on respiratory function and nutritional status in children and adults with cystic fibrosis.
P2860
Q30480308-02B8A096-6272-46A1-8910-D4B723C3FB1DQ33373854-5EF09202-919B-406E-9042-50C8CF45D220Q34179764-B5F8ACA6-DC79-43A9-A336-01393A2197F1Q34491552-42284B14-C92C-4666-9926-1DD298139329Q35232256-8ABAD5B1-005B-48FE-93EF-F4971291CAF2Q36399043-3DFAD72F-A7CF-4C60-A5B9-951A0930B0AEQ36437025-88B4A4C6-2C56-45DA-83EF-060CAA6C8C96Q36490621-D8959F80-5927-4C27-A10C-A87D96D9C601Q36910022-00F16EC6-7908-4A93-873B-2F28122D3FD2Q37070495-2C2A4155-0F0F-464D-BF0E-AA6F82013BAFQ37164477-5AA269F8-FDE5-4915-A9ED-6C35C08D2E04Q37463875-E89ACE52-61DB-4242-9F61-627E0C183FEAQ37679750-62AD0D9C-1D9F-4CCA-B9E1-4233F432E4AAQ37858512-DB45DD53-C1BC-48EB-B414-195CDFDA0528Q38248996-782D6D03-685C-45B7-93A5-12FF6AC2FBEEQ38532426-FFAD1888-4C63-4A12-80EB-29BB90962D6EQ38922548-A0872003-7442-4CD3-B7F7-09CE2973C7D3Q39578759-654FAE83-1EA7-455D-8967-4409CD7E257AQ40160990-143328D4-F923-4F13-AC96-C4B8D181F1ADQ40973759-9418F3CB-1997-4FE5-A721-2C5812F5037CQ42733334-C19D6F88-5D6F-4388-A791-42C80008E090Q42751901-3BC35CA3-3BBB-4817-A5AB-58E0DB3BB529Q44462396-2878EA58-15B9-4A32-AB2C-35F3A2DB92B0Q44558476-CF05A4EB-F246-45E6-8091-ED0DEE6FAF9CQ45346313-7F2B704A-4F1D-4F71-BB29-28D7A66A2B9BQ45375226-91C70D05-C091-48C4-8E58-67E5F87527C3Q45588440-158E685E-BCC0-4179-8780-7515F42038D3Q47136819-7E3D01FE-50D7-4172-8A35-4F214EB0614AQ47381971-570C5321-B4FA-4119-A407-DF61C99C2CC2Q47701149-194297C6-DBFB-4D01-A159-BB5BC0B63ACFQ47847809-D68C91A5-DD9F-4544-8C92-CD74D45556A8Q48201527-F1692754-AE45-4272-A6ED-37BDF101F5A4Q50987887-19220FE5-576A-462B-A0AB-8A97DA83741AQ51175537-3A5A2845-604C-47A7-83B0-A1615B9641AB
P2860
Improving rate of decline of FEV1 in young adults with cystic fibrosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Improving rate of decline of FEV1 in young adults with cystic fibrosis.
@ast
Improving rate of decline of FEV1 in young adults with cystic fibrosis.
@en
type
label
Improving rate of decline of FEV1 in young adults with cystic fibrosis.
@ast
Improving rate of decline of FEV1 in young adults with cystic fibrosis.
@en
prefLabel
Improving rate of decline of FEV1 in young adults with cystic fibrosis.
@ast
Improving rate of decline of FEV1 in young adults with cystic fibrosis.
@en
P2093
P2860
P356
P1433
P1476
Improving rate of decline of FEV1 in young adults with cystic fibrosis.
@en
P2093
P2860
P304
P356
10.1136/THX.2005.043372
P407
P577
2005-12-29T00:00:00Z